Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
ommekeer draadje niet te bereiken
Volgen
na de post van kerremelk was het draadje niet meer te bereiken.... had het te maken met de link die hij er op zette.....
via tablet (firefox browser) niet. Via pc, (chrome) in ieder geval wel.
heb ook pc geprobeerd maar dat lukte ook niet. Je kan alle forums bekijken behalve laatste post bij het ommekeer forum.
ik heb het gelezen maar wou het vertalen en alles was weg ,ga het proberen via geschiedenis terug op te vragen ik vond en vind dit raar
nu geraak ik er weer niet op het oude draadje
Probeer dit eens te lezen
“anticipates” and words of similar import. Any statement in these materials that is not a statement of historical fact is a forward-looking statement that involves known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. None of the future projections, expectations, estimates or prospects in this document should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in this document. The Company assumes no obligations to update any forward-looking statements contained herein to reflect actualresults, changes in assumptions or changes in factors affecting these statements. This document and its contents are confidential and are being provided to you solely for your information and may not be retransmitted, further distributed to any other person or published, in whole or in part, by any medium or in any form for any purpose. Any reproduction of this information, in whole or in part, is prohibited. The opinions and statements presented herein are based on general information gathered atthe time of writing and are subjectto change without notice. The Company relies on information obtained from sources believed to be reliable but does not guarantee its accuracy or completeness. No reliance may be placed for any purposes whatsoever on the information contained in this document or any other materials or on its completeness, accuracy or fairness. The information in this document is subject to verification, completion and change. Accordingly, no representation or warranty, express orimplied, is made or given by or on behalf of the Company or any of its shareholders, directors, officers or
in this Presentation. The use of amethodology otherthan the one used herein may resultin different and possibly lower Returns. This document is an advertisement forthe purposes of the applicable measures implementing the Prospectus Directive. No prospectus is required in accordance with the Prospectus Directive in relation to the Consent Solicitation. The securities described herein have not been and will not be registered underthe Securities Act or any US state securities laws orthe laws of any otherjurisdiction, and the Company will not be registered as an “investment company” undertheUS Investment Company Act of 1940 (the “Investment Company Act”). This documentis not being distributed to, and the securities described herein may not be offered or sold within the United States orto, orforthe account or benefit of, a US person (a "US Person") as defined in Rule 902(k) underthe Securities Act, except pursuantto an exemption from, orin a transaction not subject to, the Securities Act. Accordingly, each recipient of this document and each owner of the securities must be either (A) not a US Person and located outside the United States or (B) (i) a qualified institutional buyer (‘QIB’) as defined in Rule 144A under the Securities Act or an accredited investor (‘AI’) as defined in Rule 501(a) under the Securities Act and also (ii) a qualified purchaser (‘QP’) or a knowledgeable employee (‘KE’) as defined in Section 2(a)(51) of, or Rule 3c-5(a)(4) under, the Investment Company Act. This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, failing within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). Any investment activity to which this communicationmay relate is only available to, and any invitation, offer, or agreementto engage in such investment activity will be engaged in only with,relevant persons. Any person who is not a relevant person should not act orrely on this document or any of its contents. The information in this document is given in confidence and the recipients of this document should not engage in any behaviour in relation to qualifying investments or related investments (as defined in the
employees or any other person as to the accuracy, completeness or fairness of the information or opinions contained in this document. This document includes certain preliminary financial information forthe 12 months ended 31 December 2012. The Company has not completed its year-end financial review process, and so this preliminary financial information is subject to change , and such changes could be material. The Company intends to publish its audited financial statements forthe year ended 31 December 2012 in the second half of March 2013 (which date may fall afterthe end of the solicitation period). The Company can give no assurance as to whetherthe contents of such financial information would be consistent with the preliminary 2012 financialresults published on 28 February 2012 ,or material forthe purposes of your decision to consent to the Written Resolution, if such financial information were available now. None ofthe Company nor any of its shareholders, directors, officers or employees northe Managers nor any oftheir shareholders, affiliates (within the meaning of Rule 405 underthe US Securities Act of 1933 (the "Securities Act")), directors, officers or employees nor any other person accepts any liability (in negligence or otherwise) whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith. Neither the Company nor its advisers and/or agents undertake any obligation to provide the recipient with access to any additional information or to update this document or any additional information orto correct any inaccuracies in any such information whichmay become apparent. Convertible Securityholders are required to make their own independent investigation and appraisal of the business and financial condition of the Company and neither the Company, the Trustee or any other person has authorised an third party tomake such a recommendation. This document does not constitute a recommendation to participate in the Consent Solicitation. Any offer of securities to the public that may be deemed to be made pursuant to this document in any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementingmeasures in any Member State,the "ProspectusDirective")is only addressed to qualified investors in that Member State within themeaning ofthe Prospectus Directive. Internal rates ofreturn and yields. To Fortress’s knowledge, there are no established standards forthe calculation of internalrates ofreturn or yields (“Returns”) for investment portfolios of the sort discussed
Financial Services and Markets Act 2000 (FSMA) and the Code of Market Conduct made pursuant to FSMA) which would ormight amounttomarket abuse forthe purposes of FSMA.? Eurocastle Investment Ltd. (“Eurocastle”) is a publicly traded European property company externally managed by an affiliate of Fortress Investment Group (“Fortress”) with a current market cap of €34 million(1) ? Eurocastle’s current financial situation does not accommodate the servicing of its convertible debt on a current basis ? The Company proposes to clean up its capital structure by re-striking the conversion price from €0.30 to €0.05 per share in exchange for the right to require conversion. Conditional on such conversion, Fortress and the Company have agreed to rebase the management fee calculation, thereby preserving capital for investment ? Initially going to concentrate on new investment opportunities around distressed Italian loans and real estate ? Convertible security holders’ approval is required by March 28th to implement the proposed changes Executive Summary Page 2 Proposal: ? Restructure the terms of the convertible debt ? Rebase management fee to preserve cash for investment and anticipated resumption of dividend ? Shift investment focus to new asset class (1)
ging het hierover denk het wel
is dit niet een omweg naar de grote ommekeer op iex werkt hij niet maar bij debeurs wel! werkt ookwww.debeurs.nl/Forum/Topic/1296304/La...
De moderator, kon die lange onsamenhangende tekst van Kerremelker waarschijnlijk niet aan. LOL Al het goede komt van kerremelk-koeien!
die link naar de presentatie -een PDF op eurocastle site, die zichtbaar was indien je land UK en landkode 44 opgaf- opent bij mij steeds in een nieuw tabblad. Als uw browser die link opent in zelfde venster, dan moest je terugkeren. De screenshot bijlage was berekend met cijfers uit kwartaal 4. Ook die bijlage opende hier in nieuw tabblad. Het soms niet kunnen posten (forum topic niet gevonden) heeft allicht te maken met hoe de forum software omgaat met edits in bestaande berichten, en plaatsen v. nieuwe berichten tezelfdertijd. JT
komen de cijfers nou morgen of niet? ik las in vorige forums dat op 22 maart de cijfers over 2012 komen
ja, die cijfers worden morgen geplaatst. Eurocastle Investment Ltd. : quaterly earnings release 03/19/2013| 10:15am US/Eastern The company will report its earnings for Q4 2012 on 03/22/2013. Generally, the company reports earnings worse than estimates. In recent months, the analysts from Thomson Reuters consensus have revised their EPS estimates downward. © 4-traders.com 2013
Op 4 traders staat een zinnetje....the company reports earning worse than estimated. Ben benieuwd morgen, waar ze mee gaan komen ten opzichte van de recente voorspelling vd jr cijfers. Valt het mee dan blijft de bied op de .05 staan, zijn ze nog rotter dan eerder naar buiten gebracht, dan vermoed ik weinig biedingen in de .05. We gaan het mañana wel zien wat er gebeurt.
Ja zeker maar verkopen heeft ook geen zin ,doe je teveel verlies mee eens zal het wel terug stijgen ,en wat is consenseus van een aandeel ze zeggen ook geen getal he wat het nu waard is het aandeel van ect binnenkort kunnen we verkopen met 3 cijfers achter de komma.
Hi, dat laatste vroeg ik me ook al dikwijls af. Hangt dat af van het aantal aandelen of niet? Of hangt dat af van beurs kapitalisatie? We gaan dat weten in juni 2013 zeker? Met spreads van 1 volle cent zoals nu, of niet, kan veel verschil uitmaken voor de toekomst. Jaak
Wat is dat met het forum ,de zin opbouw wordt op een andere manier doorgegeven .Of kunnen wij niet meer schrijven ,,,
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee